SU
Supernus Pharmaceuticals
SUPN13F as of Jun 30, 2026 · next update ~Nov 14
Limited coverage
Only 1 fund we track owns this stock, so quarterly sentiment and aggregates may be sparse.
Who's buying SUPN
Top funds mostly trimmed Supernus Pharmaceuticals in Q1 (Jan–Mar)
Buying:
FundsInsidersCongress1
- Top funds0 of 1 bought more, 1 sold some. Largest: Third Avenue Management, $7.1M (1% of its portfolio).
- InsidersNo buys, 8 sales in 12 months.
- Congress1 member bought (2 trades), 0 sales in 12 months.
1 fund$7.1M held1.1% avg. weightQ1: 0 bought / 1 sold
13F reports are a snapshot as of Mar 31, 2026; funds may have traded since. Insiders often sell for personal reasons (taxes, diversification, planned sales).
Share price · market data, not from 13F reports
Q2 2026